Anthim injection approved to treat inhalational anthrax
U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent
Anthrax
Anthrax is a bacterial infection caused by Bacillus anthracis that primarily affects livestock but that can occasionally spread to humans, affecting either the skin, intestines, or lungs. In humans, the infection can often be treated, but it is almost always fatal in animals.
Anthrax exposure in CDC Lab USA
US CDC says more lab workers may have been exposed to anthrax – CDC announced that approximately 75 Atlanta-based staff are being monitored or provided antibiotics because they may have been unintentionally exposed to live Bacillus anthracis (anthrax) after established safety practices were not followed.
US to bulk purchase BioThrax anthrax vaccine from Emergent BioSolutions
U.S. Government to Purchase Additional 14.5 Million Doses of BioThrax under New Contract Valued at up to $404 Million. – Emergent BioSolutions Inc. (NYSE:EBS) announced that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and Human Services (HHS) to supply an additional 14.5 million doses of BioThrax(R) (Anthrax Vaccine Adsorbed), its FDA licensed anthrax vaccine, for inclusion in the Strategic National Stockpile (SNS).